Microneedles for enhanced transdermal and intraocular drug delivery
Microneedles for enhanced transdermal and intraocular drug delivery
复制标题
DOI：
10.1016/j.coph.2017.07.007
复制
发表时间：
2017-10-01
影响因子：
4
通讯作者：
Donnelly, Ryan F.
中科院分区：
文献类型：
--
作者：
Moffatt, Kurtis;Wang, Yujing;Donnelly, Ryan F.
近年来，基于微针介导的给药研究引起了极大的兴趣。在过去，最初的重点是生物来源的大分子的递送，然而该领域现在已经扩大了其范围，包括传统的低分子量药物分子的透皮递送。利用这一方法取得了巨大成功，特别是在疫苗提供领域。目前的技术进步使设计配方得到了改进，在更大的贴片尺寸和可扩展的制造的帮助下，可以提供治疗剂量的小分子药物和生物分子。此外，最近有研究表明，微针有助于靶向眼组织内药物输送系统的定位。微针有能力改变治疗药物和配方进入眼睛的方式。然而，由于潜在的缺点和挑战，仍然需要进一步的研究。事实上，目前还没有真正的基于微针的经皮或眼部给药系统上市。人们对此类系统的管理问题和制造过程提出了一些关切，目前该领域的人员正在积极努力解决这些问题。基于微针的透皮和眼部给药系统不仅对患者的利益有很大的影响，而且对行业也有很大的影响，通过勤奋、创新和合作，它们的真正潜力将在未来3-5年内开始实现。
Microneedle mediated delivery based research has garnered great interest in recent years. In the past, the initial focus was delivery of macromolecules of biological origin, however the field has now broadened its scope to include transdermal delivery of conventional low molecular weight drug molecules. Great success has been demonstrated utilising this approach, particularly in the field of vaccine delivery. Current technological advances have permitted an enhancement in design formulation, allowing delivery of therapeutic doses of small molecule drugs and biomolecules, aided by larger patch sizes and scalable manufacture. In addition, it has been recently shown that microneedles are beneficial in localisation of drug delivery systems within targeted ocular tissues. Microneedles have the capacity to modify the means in which therapeutics and formulations are delivered to the eye. However, further research is still required due to potential drawbacks and challenges. Indeed, no true microneedle-based transdermal or ocular drug delivery system has yet been marketed. Some concerns have been raised regarding regulatory issues and manufacturing processes of such systems, and those in the field are now actively working to address them. Microneedle-based transdermal and ocular drug delivery systems have the potential to greatly impact not only patient benefits, but also industry, and through diligence, innovation and collaboration, their true potential will begin to be realised within the next 3-5 years.